CSL Limited (CSLLY)
(Delayed Data from OTC)
$100.29 USD
-0.47 (-0.46%)
Updated Sep 20, 2024 03:07 PM ET
4-Sell of 5 4
C Value B Growth B Momentum B VGM
Average Brokerage Rating
Current ABR | 1.57 |
ABR (Last week) | 1.57 |
# of Recs in ABR | 7 |
Average Target Price | $110.00 |
LT Growth Rate | 14.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 85 of 253 |
Current Quarter EPS Est: | NA |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 6 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.57 | 1.57 | 1.50 | 1.57 | 1.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | Not Identified | Not Identified | Hold | Hold |
8/13/2024 | Macquarie Capital Securities | David Bailey | Not Available | Strong Buy |
2/20/2024 | UBS | Laura Sutcliffe | Strong Buy | Strong Buy |
2/14/2024 | Not Identified | Not Identified | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.